6-OH-dopa is reported to suppress RAD52 recruitment and recombination activity in vitro (by disrupting RAD52 heptamer and undecamer ring superstructures), selectively inhibiting the proliferation of BRCA deficient cancer cells. Here, RAD52 is linked to cancer.